

Resource Summary Report

Generated by [dkNET](#) on Aug 31, 2026

FGF Receptor 3 (C51F2)

RRID:AB_2246903

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4574, RRID:AB_2246903

Antibody Information

URL: http://antibodyregistry.org/AB_2246903

Proper Citation: Cell Signaling Technology Cat# 4574, RRID:AB_2246903

Target Antigen: FGFR3

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC. Consolidation on 11/2018: AB_10287934, AB_2246903, AB_2721171.

Antibody Name: FGF Receptor 3 (C51F2)

Description: This monoclonal targets FGFR3

Target Organism: human

Clone ID: C51F2

Antibody ID: AB_2246903

Vendor: Cell Signaling Technology

Catalog Number: 4574

Record Creation Time: 20250820T055130+0000

Record Last Update: 20250820T223829+0000

Ratings and Alerts

No rating or validation information has been found for FGF Receptor 3 (C51F2).

No alerts have been found for FGF Receptor 3 (C51F2).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.

Juric D, et al. (2026) PI3K?? Inhibitor and Degradar Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 56.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. *NPJ breast cancer*, 11(1), 135.

Chamessian A, et al. (2025) Expression of Fibroblast Growth Factor Receptor 3 (FGFR3) in the Human Peripheral Nervous System: Implications for the Putative Pathogenic Role of FGFR3 Autoantibodies in Neuropathy. *bioRxiv : the preprint server for biology*.

Ye T, et al. (2024) Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma. *Cell reports*, 43(5), 114211.

Yang Y, et al. (2024) A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants. *Cancer research*, 84(13), 2169.

Gou X, et al. (2023) Kinome reprogramming is a targetable vulnerability in ESR1 fusion-driven breast cancer. *Cancer research*.

Ma L, et al. (2023) Discovery of a Selective and Orally Bioavailable FGFR2 Degradar for Treating Gastric Cancer. *Journal of medicinal chemistry*, 66(11), 7438.

Di Persio S, et al. (2021) Single-cell RNA-seq unravels alterations of the human spermatogonial stem cell compartment in patients with impaired spermatogenesis. *Cell reports. Medicine*, 2(9), 100395.

Vigneswaran K, et al. (2021) YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(5), 1553.

Day EK, et al. (2020) Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling. *Cell reports*, 30(10), 3383.

Oberlick EM, et al. (2019) Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. *Cell reports*, 28(9), 2331.

Zhang W, et al. (2018) Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth. *Cell reports*, 24(5), 1266.